University of North Carolina Lineberger Comprehensive Cancer Center
Welcome,         Profile    Billing    Logout  
 41 Trials 
69 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Socinski, Mark A
AdvanTIG-302, NCT04746924 / 2020-004985-21: A Study of Ociperlimab With Tislelizumab Compared to Pembrolizumab in Participants With Untreated Lung Cancer

Active, not recruiting
3
662
Europe, Japan, US, RoW
Tislelizumab, BGB-A317, Ociperlimab, BGB-A1217, Pembrolizumab, KEYTRUDA, Placebo
BeiGene
Non-small Cell Lung Cancer, NSCLC
10/26
02/27
PRESERVE-003, NCT05671510: ONC-392 Versus Docetaxel in Metastatic NSCLC That Progressed on PD-1/PD-L1 Inhibitors

Active, not recruiting
3
600
Europe, Canada, US, RoW
Gotistobart, A humanized anti-CTLA4 IgG1 monoclonal antibody, ONC-392, BNT316, Docetaxel, Docefrez, Taxotere
OncoC4, Inc., BioNTech SE
Non Small Cell Lung Cancer
06/26
06/27
PRESERVE-001, NCT04140526: Safety, PK and Efficacy of ONC-392 in Monotherapy and in Combination of Anti-PD-1 in Advanced Solid Tumors and NSCLC

Recruiting
1/2
733
US, RoW
ONC-392, A humanized anti-CTLA4 IgG1 monoclonal antibody made by OncoC4, Inc., Pembrolizumab, Keytruda, MK3475, Docetaxel, Taxotere, Docefrez
OncoC4, Inc., National Cancer Institute (NCI)
Non Small Cell Lung Cancer, Advanced Solid Tumor, Metastatic Melanoma, Metastatic Head and Neck Carcinoma, Metastatic Renal Cell Carcinoma, Metastatic Colorectal Cancer, Sarcomas, Metastatic Prostate Cancer, Ovarian Cancer, Small Cell Lung Cancer, Metastatic Breast Cancer, Pancreas Cancer, Gastric Cancer, Esophageal Cancer, Gastroesophageal Junction Adenocarcinoma, Cervical Cancer, Adenoid Cystic Carcinoma, Salivary Gland Cancer, Urothelial Carcinoma
06/26
12/27
REZILIENT1, NCT04036682: A Phase 1/2 Trial of CLN-081 in Patients with Non-Small Cell Lung Cancer

Checkmark Data from a trial for NSCLC
Jan 2022 - Jan 2022: Data from a trial for NSCLC
Active, not recruiting
1/2
284
Europe, Japan, US, RoW
CLN-081, TAS6417; zipalertinib
Cullinan Therapeutics Inc.
Non Small Cell Lung Cancer, EGFR Exon 20 Mutation
12/24
12/24
ELVN-002-001, NCT05650879: ELVN-002 in HER2 Mutant Non-Small Cell Lung Cancer

Recruiting
1
198
Europe, US, RoW
ELVN-002, Fam-Trastuzumab Deruxtecan-Nxki, Enhertu, T-DXd, Trastuzumab emtansine, Kadcyla, T-DM1
Enliven Therapeutics
HER2 Mutant Non-small Cell Lung Cancer, HER2-positive Metastatic Breast Cancer, HER2 Gene Mutation, HER2 Amplification
07/26
07/26
NCT03906331: Expanded Access for the Treatment of Cancers With Rearranged During Transfection (RET) Activation

Approved for marketing
N/A
Europe, Japan, US, RoW
Selpercatinib, LOXO-292, LY3527723
Eli Lilly and Company, Eli Lilly and Company
Non Small Cell Lung Cancer, Medullary Thyroid Cancer, Colon Cancer, Breast Cancer, Pancreatic Cancer, Papillary Thyroid Cancer, Other Solid Tumors With Evidence of Activating RET Alteration
 
 
CYBRID-02, NCT05520099: Observational Basket Trial to Collect Tissue to Train and Validate a Live Tumor Diagnostic Platform

Recruiting
N/A
216
US
Core Needle or Forceps Biopsy
Elephas, Hoosier Cancer Research Network
Colorectal Cancer, Head and Neck Squamous Cell Carcinoma, Non Small Cell Lung Cancer, Cutaneous Melanoma, Endometrial Cancer, Urothelial Carcinoma, Clear Cell Renal Cell Carcinoma
01/27
01/27
Stinchcombe, Thomas
NCT04929041: Testing the Addition of Radiation Therapy to the Usual Treatment (Immunotherapy With or Without Chemotherapy) for Advanced Stage Non-small Cell Lung Cancer Patients Who Are PD-L1 Negative

Recruiting
2/3
427
US
Biopsy, BIOPSY_TYPE, Bx, Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Computed Tomography, CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized axial tomography (procedure), Computerized Tomography, Computerized Tomography (CT) scan, CT, CT Scan, tomography, Echocardiography, EC, Ipilimumab, Anti-Cytotoxic T-Lymphocyte-Associated Antigen-4 Monoclonal Antibody, BMS 734016, BMS-734016, BMS734016, Ipilimumab Biosimilar CS1002, MDX 010, MDX-010, MDX-CTLA4, MDX010, Yervoy, Magnetic Resonance Imaging, Magnetic Resonance, Magnetic Resonance Imaging (MRI), Magnetic resonance imaging (procedure), Magnetic Resonance Imaging Scan, Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance, MR, MR Imaging, MRI, MRI Scan, MRIs, NMR Imaging, NMRI, Nuclear Magnetic Resonance Imaging, sMRI, Structural MRI, Nivolumab, ABP 206, BCD-263, BMS 936558, BMS-936558, BMS936558, CMAB819, MDX 1106, MDX-1106, MDX1106, NIVO, Nivolumab Biosimilar ABP 206, Nivolumab Biosimilar BCD-263, Nivolumab Biosimilar CMAB819, ONO 4538, ONO-4538, ONO4538, Opdivo, Positron Emission Tomography, Medical Imaging, Positron Emission Tomography, PET, PET Scan, Positron emission tomography (procedure), Positron Emission Tomography Scan, Positron-Emission Tomography, proton magnetic resonance spectroscopic imaging, PT, Quality-of-Life Assessment, Quality of Life Assessment, Radiation Therapy, Cancer Radiotherapy, Energy Type, ENERGY_TYPE, Irradiate, Irradiated, Irradiation, Radiation, Radiation Therapy, NOS, Radiotherapeutics, Radiotherapy, RT, Therapy, Radiation
National Cancer Institute (NCI)
Lung Adenocarcinoma, Lung Adenosquamous Carcinoma, Lung Non-Small Cell Carcinoma, Stage IIIB Lung Cancer AJCC v8, Stage IIIC Lung Cancer AJCC v8, Stage IV Lung Cancer AJCC v8
12/27
12/27
NCT04099836: Atezolizumab and Bevacizumab in EGFR Mutant NSCLC in Patients With Progressive Disease After Receiving Osimertinib

Terminated
2
7
US
Atezolizumab, TECENTRI, Bevacizumab, Avastin
Duke University
Non Small Cell Lung Cancer
11/22
06/23
SGNTUC-019, NCT04579380 / 2020-004873-29: Basket Study of Tucatinib and Trastuzumab in Solid Tumors With HER2 Alterations

Active, not recruiting
2
217
Europe, Japan, US, RoW
tucatinib, TUKYSA, ARRY-380, ONT-380, trastuzumab, Herceptin, fulvestrant, Faslodex
Seagen Inc., Seagen, Inc.
Uterine Neoplasms, Uterine Cervical Neoplasms, Biliary Tract Neoplasms, Urologic Neoplasms, Carcinoma, Non-Small-Cell Lung, HER2 Mutations Breast Neoplasms
11/23
05/25
ALKOVE-1, NCT05384626 / 2022-000122-21: A Study of NVL-655 in Patients With Advanced NSCLC and Other Solid Tumors Harboring ALK Rearrangement or Activating ALK Mutation

Recruiting
1/2
470
Europe, Canada, Japan, US, RoW
NVL-655
Nuvalent Inc., Nuvalent, Inc.
Locally Advanced Solid Tumor, Metastatic Solid Tumor
02/26
03/26
Morris, David
VERACITY, NCT04844749: Efficacy Evaluation of VERU-111 for mCRPC in Patients Who Have Failed at Least One Androgen Receptor Targeting Agent

Terminated
3
105
US
VERU-111, Sabizabulin, Enzalutamide, Abiraterone, XTANDI, Zytiga
Veru Inc.
Metastatic Castration-resistant Prostate Cancer, Androgen Resistant Prostatic Cancer
05/23
05/23
CLARIFY, NCT06056830: Positron Emission Tomography Using 64Cu-SAR-bisPSMA in Participants With High-risk Prostate Cancer Prior to Radical Prostatectomy

Recruiting
3
383
US, RoW
64Cu-SAR-bisPSMA
Clarity Pharmaceuticals Ltd
Prostate Cancer, Prostatic Neoplasms
02/25
02/25
NCT05903131: A Behavioral Intervention to Promote Primary Prevention and Uterine Preservation in Premenopausal Women With Obesity and Endometrial Hyperplasia

Recruiting
2
96
US
Telemedicine behavioral weight intervention, Progestin, Enhanced usual care, Levonorgestrel-releasing IUD.
Washington University School of Medicine, National Cancer Institute (NCI)
Endometrial Hyperplasia, Grade 1 Endometrial Cancer
10/28
10/29
NCT05829460: Primary Prevention and Uterine Preservation in Premenopausal Women With Obesity and Endometrial Hyperplasia

Not yet recruiting
2
96
US
Semaglutide, Placebo, LNG-IUD (Progestin), Telemedicine behavioral weight program
Washington University School of Medicine, Novo Nordisk A/S
Endometrial Hyperplasia
12/29
12/31
CELLO-1, NCT04179864 / 2019-003649-14: A Study of Tazemetostat With Enzalutamide or Abiraterone/Prednisone in Participants With Advanced Prostate Cancer

Checkmark Data from CELLO-1 trial for CRPC at SUO 2022
Dec 2022 - Dec 2022: Data from CELLO-1 trial for CRPC at SUO 2022
Checkmark Safety data from P1b portion of P1b/2 trial in combination with enzalutamide or with abiraterone/prednisone for CRPC at ESMO 2021
Sep 2021 - Sep 2021: Safety data from P1b portion of P1b/2 trial in combination with enzalutamide or with abiraterone/prednisone for CRPC at ESMO 2021
Terminated
1/2
102
Europe, US
Tazemetostat, EPZ-6438, E7438, IPN60200, Abiraterone/prednisone, Zytiga, Enzalutamide, Xtandi
Epizyme, Inc.
Metastatic Prostate Cancer, Metastatic Castration-resistant Prostate Cancer
11/24
11/24
NCT05497934: The Effects of Glycerol as an Optical Clearing Agent for Visualization of the Middle Ear

Withdrawn
1
50
NA
Glycerol, Glycerin(e)
Nova Scotia Health Authority, Dalhousie University
Tympanosclerosis, Thickened Ears, Healthy, Surgery
10/23
03/24
PRL-02-1001, NCT04729114: A Safety and Dose-finding Study of PRL-02 Depot in Men With Advanced Prostate Cancer

Recruiting
1
174
US
PRL-02 injection, prednisone, dexamethasone, enzalutamide
Astellas Pharma Global Development, Inc.
Prostate Cancer, Metastatic Castration Resistant Prostate Cancer, Metastatic Castration-sensitive Prostate Cancer
08/25
05/29
NCT05492513: Constraint-Induced Movement Therapy for Adults Post-Stroke With Mild Upper Extremity Impairment

Recruiting
N/A
12
US
Grade 1 CI Therapy +Sensory Components
University of Alabama at Birmingham
CVA (Cerebrovascular Accident), Stroke, Upper Extremity Paresis
11/25
03/26
NCT05515237: Constraint-Induced Movement Therapy Plus Sensory Components After Stroke

Recruiting
N/A
15
US
Grade 2-5 CI Therapy + Sensory Components
University of Alabama at Birmingham
CVA (Cerebrovascular Accident), Stroke, Upper Extremity Paresis
03/26
06/26
NCT06310278: Ossiview Normative Mobility Data Collection Protocol

Recruiting
N/A
120
Canada
Ossicular mobility measurement
Audioptics Medical Incorporated
Conductive Hearing Loss, Middle Ear
10/24
10/24
CISTO, NCT03933826: Comparison of Intravesical Therapy and Surgery as Treatment Options for Bladder Cancer

Active, not recruiting
N/A
572
US
University of Washington, Patient-Centered Outcomes Research Institute
Bladder Cancer, Cancer of the Bladder, Recurrent, Non-muscle Invasive Bladder Cancer
12/24
03/25
Moschos, Stergios
ADAM, NCT03271372: Adjuvant Avelumab in Merkel Cell Cancer

Jan 2024 - Dec 2024: From trial
Active, not recruiting
3
101
US
Avelumab, Bavencio, MSB-0010718C, MSB0010718C, Peripheral Blood Collection, Placebo, placebo therapy, PLCB, normal saline solution
University of Washington, EMD Serono
Stage III Merkel Cell Carcinoma AJCC v8, Stage IIIB Merkel Cell Carcinoma AJCC v8, Stage IIIA Merkel Cell Carcinoma AJCC v8
04/26
02/29
NCI9922, NCT02581930: Ibrutinib in Treating Patients With Refractory Metastatic Cutaneous Melanoma

Active, not recruiting
2
18
US
Ibrutinib, BTK Inhibitor PCI-32765, CRA 032765, CRA-032765, CRA032765, Imbruvica, PCI 32765, PCI-32765, PCI32765, Laboratory Biomarker Analysis, Pharmacogenomic Study, PHARMACOGENOMIC, Pharmacological Study
National Cancer Institute (NCI)
Metastatic Melanoma, Recurrent Cutaneous Melanoma, Stage IV Cutaneous Melanoma AJCC v6 and v7
02/18
03/25
NCT03427398: Ibrutinib in Treating Patients With Refractory Metastatic Cutaneous Melanoma

Active, not recruiting
2
18
US
Ibrutinib, BTK Inhibitor PCI-32765, CRA-032765, Imbruvica, PCI-32765, Laboratory Biomarker Analysis, Pharmacogenomic Study, PHARMACOGENOMIC, Pharmacological Study
National Cancer Institute (NCI)
Metastatic Melanoma, Recurrent Melanoma of the Skin, Stage IV Cutaneous Melanoma AJCC v6 and v7
02/18
 
NCT03089606: Pembrolizumab TX-naive Distant Mets Melanoma and Use of (C11-AMT) PET at Baseline as Imaging Biomarker

Completed
2
27
US
FDG PET/CT scan, C11-AMT PET scan, Pembrolizumab, Keytruda, CT scan
UNC Lineberger Comprehensive Cancer Center, Merck Sharp & Dohme LLC
Melanoma
04/21
07/23
NCT03765229: An Exploratory Study of Pembrolizumab Plus Entinostat in Non-Inflamed Stage III/IV Melanoma

Completed
2
11
US
Entinostat, Pembrolizumab, Keytruda
UNC Lineberger Comprehensive Cancer Center, Syndax Pharmaceuticals
Melanoma
12/22
07/23
NCT03620019: Denosumab + PD-1 in Subjects With Stage III/ IV Melanoma

Completed
2
25
US
Denosumab, XGEVA, Pembrolizumab, Keytruda, Nivolumab, Opdivo
UNC Lineberger Comprehensive Cancer Center, Amgen
Melanoma Stage Iii, Melanoma Stage Iv, Melanoma, Melanoma (Skin), Cutaneous Melanoma
04/23
08/23
NCT04462406: Using Biomarkers to Help Guide Safe Immunotherapy Discontinuation in Patients With Unresectable Stage IIIB-IV Melanoma, The PET-Stop Trial

Recruiting
2
150
US
Ipilimumab, Anti-Cytotoxic T-Lymphocyte-Associated Antigen-4 Monoclonal Antibody, BMS-734016, MDX-010, MDX-CTLA4, Yervoy, Nivolumab, BMS-936558, MDX-1106, NIVO, ONO-4538, Opdivo, Patient Observation, Active Surveillance, deferred therapy, expectant management, Observation, Watchful Waiting, Pembrolizumab, Keytruda, Lambrolizumab, MK-3475, SCH 900475
ECOG-ACRIN Cancer Research Group, National Cancer Institute (NCI)
Advanced Melanoma, Clinical Stage III Cutaneous Melanoma AJCC v8, Clinical Stage IV Cutaneous Melanoma AJCC v8, Melanoma of Unknown Primary, Pathologic Stage IIIB Cutaneous Melanoma AJCC v8, Pathologic Stage IIIC Cutaneous Melanoma AJCC v8, Pathologic Stage IIID Cutaneous Melanoma AJCC v8, Pathologic Stage IV Cutaneous Melanoma AJCC v8, Unresectable Acral Lentiginous Melanoma, Unresectable Melanoma, Unresectable Mucosal Melanoma
08/26
08/26
NCT04381650 / 2020-004325-23: A Study of TAK-981 Given With Pembrolizumab in Participants With Select Advanced or Metastatic Solid Tumors

Active, not recruiting
1/2
49
Europe, Japan, US, RoW
TAK-981, Pembrolizumab
Takeda, Takeda Development Center Americas, Inc.
Advanced or Metastatic Solid Tumors
11/25
11/25
Thompson, Patrick A
NCT02945800: Nab-Paclitaxel and Gemcitabine for Recurrent/Refractory Sarcoma

Active, not recruiting
2
59
US
nab-Paclitaxel, Abraxane, Gemcitabine, Gemzar
H. Lee Moffitt Cancer Center and Research Institute, National Pediatric Cancer Foundation
Osteosarcoma, Ewing Sarcoma, Rhabdomyosarcoma, Soft Tissue Sarcoma
02/25
02/26
NCT04388839: Evolutionary Therapy for Rhabdomyosarcoma

Recruiting
2
28
US
Vincristine, Cyclophosphamide, Vinorelbine, Navelbine, Actinomycin D, Cosmegen, Cyclophosphamide Pill
H. Lee Moffitt Cancer Center and Research Institute, National Pediatric Cancer Foundation
Rhabdomyosarcoma
08/26
08/27
CA209-9WW, NCT03628209: Nivolumab or Nivolumab and Azacitidine in Patients With Recurrent, Resectable Osteosarcoma

Active, not recruiting
1/2
21
US
Nivolumab, Opdivo®, Azacitidine, Vidaza®, Post Treatment Surgery, Standard of Care, Resection of disease
H. Lee Moffitt Cancer Center and Research Institute, Bristol-Myers Squibb
Osteosarcoma, Osteosarcoma in Children, Osteosarcoma Recurrent, Sarcoma
12/24
12/25
NCT04337177: Flavored, Oral Irinotecan VAL-413 (Orotecan®) Given With Temozolomide for Treatment of Recurrent Pediatric Solid Tumors

Recruiting
1
20
US
VAL-413, Orotecan®, Temozolomide, Temodar, Temodal, Temcad, TMZ
Valent Technologies, LLC
Solid Tumors, Neuroblastoma, Rhabdomyosarcoma, Ewing Sarcoma, Hepatoblastoma, Medulloblastoma
06/25
06/25
NCT01587300: Neuroblastoma Biology Study

Recruiting
N/A
1000
Canada, US
New Approaches to Neuroblastoma Therapy Consortium
Neuroblastoma
12/99
12/99
Silk, Ann
ADAM, NCT03271372: Adjuvant Avelumab in Merkel Cell Cancer

Jan 2024 - Dec 2024: From trial
Active, not recruiting
3
101
US
Avelumab, Bavencio, MSB-0010718C, MSB0010718C, Peripheral Blood Collection, Placebo, placebo therapy, PLCB, normal saline solution
University of Washington, EMD Serono
Stage III Merkel Cell Carcinoma AJCC v8, Stage IIIB Merkel Cell Carcinoma AJCC v8, Stage IIIA Merkel Cell Carcinoma AJCC v8
04/26
02/29
NCT02748564: Aldesleukin and Pembrolizumab in Treating Patients With Stage III-IV Melanoma

Terminated
2
10
US
Aldesleukin, 125-L-Serine-2-133-interleukin 2, Proleukin, r-serHuIL-2, Recombinant Human IL-2, Recombinant Human Interleukin-2, Laboratory Biomarker Analysis, Pembrolizumab, Keytruda, Lambrolizumab, MK-3475, SCH 900475
Rutgers, The State University of New Jersey, National Cancer Institute (NCI)
Metastatic Melanoma, Stage III Mucosal Melanoma of the Head and Neck, Stage IIIA Skin Melanoma, Stage IIIB Skin Melanoma, Stage IIIC Skin Melanoma, Stage IV Skin Melanoma, Stage IVA Mucosal Melanoma of the Head and Neck, Stage IVB Mucosal Melanoma of the Head and Neck, Stage IVC Mucosal Melanoma of the Head and Neck
10/18
06/23
NCI#10057, NCT02978625: Talimogene Laherparepvec and Nivolumab in Treating Patients With Refractory Lymphomas or Advanced or Refractory Non-melanoma Skin Cancers

Active, not recruiting
2
68
US
Biopsy, BIOPSY_TYPE, Bx, Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Computed Tomography, CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized axial tomography (procedure), Computerized Tomography, Computerized Tomography (CT) scan, CT, CT Scan, tomography, Laboratory Biomarker Analysis, Nivolumab, ABP 206, BCD-263, BMS 936558, BMS-936558, BMS936558, CMAB819, MDX 1106, MDX-1106, MDX1106, NIVO, Nivolumab Biosimilar ABP 206, Nivolumab Biosimilar BCD-263, Nivolumab Biosimilar CMAB819, ONO 4538, ONO-4538, ONO4538, Opdivo, Positron Emission Mammography, Talimogene Laherparepvec, ICP34.5-, ICP47-deleted Herpes Simplex Virus 1 (HSV-1) Incorporating the Human GM-CSF Gene, Imlygic, JS1 34.5-hGMCSF 47- pA-, T-VEC
National Cancer Institute (NCI)
Anaplastic Large Cell Lymphoma, ALK-Negative, Anaplastic Large Cell Lymphoma, ALK-Positive, Apocrine Carcinoma, Carcinoma Arising From Cylindroma, Carcinoma Arising From Spiradenoma, Digital Papillary Adenocarcinoma, Endocrine Mucin-Producing Sweat Gland Carcinoma, Extramammary Paget Disease, Extraocular Sebaceous Carcinoma, Hidradenocarcinoma, Malignant Sweat Gland Neoplasm, Merkel Cell Carcinoma, Microcystic Adnexal Carcinoma, NK-Cell Lymphoma, Unclassifiable, Papillary Adenocarcinoma, Porocarcinoma, Primary Cutaneous Mucinous Carcinoma, Recurrent Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma, Recurrent T-Cell Non-Hodgkin Lymphoma, Refractory Anaplastic Large Cell Lymphoma, Refractory Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma, Refractory Merkel Cell Carcinoma, Refractory Mycosis Fungoides, Refractory Primary Cutaneous T-Cell Non-Hodgkin Lymphoma, Refractory Skin Squamous Cell Carcinoma, Refractory T-Cell Non-Hodgkin Lymphoma, Sezary Syndrome, Signet Ring Cell Adenocarcinoma, Skin Adenoid Cystic Carcinoma, Skin Adnexal Carcinoma, Skin Basal Cell Carcinoma, Skin Basosquamous Cell Carcinoma, Skin Keratoacanthoma, Skin Squamous Cell Carcinoma, Squamoid Eccrine Ductal Carcinoma, Squamous Cell Carcinoma of Unknown Primary, Sweat Gland Carcinoma, Trichilemmal Carcinoma, Vulvar Squamous Cell Carcinoma
09/25
09/25
NCT05947500: Testing the Combination of Two Anticancer Drugs M1774 (Tuvusertib) and Avelumab to Evaluate Their Safety and Effectiveness in Treating Merkel Cell Skin Cancer, MATRiX Trial

Recruiting
2
50
Canada, US
Avelumab, Bavencio, MSB 0010718C, MSB-0010718C, MSB0010718C, Biopsy, BIOPSY_TYPE, Bx, Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Computed Tomography, CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized axial tomography (procedure), Computerized Tomography, Computerized Tomography (CT) scan, CT, CT Scan, tomography, Magnetic Resonance Imaging, Magnetic Resonance, Magnetic Resonance Imaging (MRI), Magnetic resonance imaging (procedure), Magnetic Resonance Imaging Scan, Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance, MR, MR Imaging, MRI, MRI Scan, MRIs, NMR Imaging, NMRI, Nuclear Magnetic Resonance Imaging, sMRI, Structural MRI, Positron Emission Tomography, Medical Imaging, Positron Emission Tomography, PET, PET Scan, Positron emission tomography (procedure), Positron Emission Tomography Scan, Positron-Emission Tomography, proton magnetic resonance spectroscopic imaging, PT, Tuvusertib, ATR Kinase Inhibitor M1774, M 1774, M-1774, M1774
National Cancer Institute (NCI)
Clinical Stage III Cutaneous Merkel Cell Carcinoma AJCC v8, Clinical Stage IV Cutaneous Merkel Cell Carcinoma AJCC v8, Locally Advanced Merkel Cell Carcinoma, Metastatic Merkel Cell Carcinoma, Refractory Merkel Cell Carcinoma, Unresectable Merkel Cell Carcinoma
01/28
01/28
START-001, NCT05592626: A Study of a Selective T Cell Receptor (TCR) Targeting, Bifunctional Antibody-fusion Molecule STAR0602 in Participants with Advanced Solid Tumors

Recruiting
1/2
365
Europe, Canada, US
STAR0602
Marengo Therapeutics, Inc.
Advanced Solid Tumors, Genital Neoplasm, Female, Urogenital Neoplasms, Lung Neoplasm, Neoplasms by Site, Papillomavirus Infection, Epstein-Barr Virus Infections, Carcinoma, Neoplasms, Vulvar Neoplasms, Vulvar Diseases, Abdominal Neoplasm
10/26
10/26
NCT04160065: Immunotherapy With IFx-Hu2.0 Vaccine for Advanced Non-melanoma Skin Cancers

Completed
1
23
US
IFx-Hu2.0, pAc/emm55
TuHURA Biosciences, Inc., H. Lee Moffitt Cancer Center and Research Institute, University of Southern California, Dana-Farber Cancer Institute, Huntsman Cancer Institute
Merkel Cell Carcinoma, Cutaneous Squamous Cell Carcinoma, Non-Melanoma Skin Cancers
10/23
08/24
Zeidner, Joshua F
NCT03258931: Study of Crenolanib vs Midostaurin Following Induction Chemotherapy and Consolidation Therapy in Newly Diagnosed FLT3 Mutated AML

Recruiting
3
510
US
Crenolanib, Crenolanib besylate, Midostaurin, Cytarabine, Duanorubicin
Arog Pharmaceuticals, Inc.
Newly Diagnosed FLT3 Mutated AML
11/22
11/24
NCT02768792: High Dose Cytarabine Followed by Pembrolizumab in Relapsed/Refractory AML

Completed
2
38
US
pembrolizumab,, KEYTRUDA, MK-3475
UNC Lineberger Comprehensive Cancer Center, Merck Sharp & Dohme LLC
Acute Myeloid Leukemia, in Relapse
11/19
06/24
NCT04802161: Comparing the Addition of an Anti-Cancer Drug, Pomalidomide, to the Usual Chemotherapy Treatment (Daunorubicin and Cytarabine Liposome) in Newly Diagnosed Acute Myeloid Leukemia With Myelodysplastic Syndrome-Related Changes

Suspended
2
78
US
Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Bone Marrow Aspiration and Biopsy, Liposome-encapsulated Daunorubicin-Cytarabine, CPX 351, CPX-351, CPX351, Cytarabine and Daunorubicin Liposomal, Cytarabine-Daunorubicin Liposome for Injection, Daunorubicin and Cytarabine (Liposomal), Liposomal AraC-Daunorubicin CPX-351, Liposomal Cytarabine-Daunorubicin, Liposome-encapsulated Combination of Daunorubicin and Cytarabine, Vyxeos, Pomalidomide, 4-Aminothalidomide, Actimid, CC 4047, CC-4047, CC4047, Imnovid, Pomalyst
National Cancer Institute (NCI)
Acute Myeloid Leukemia, Acute Myeloid Leukemia Post Cytotoxic Therapy, Acute Myeloid Leukemia With Multilineage Dysplasia, Chronic Myelomonocytic Leukemia, Myelodysplastic Syndrome, Myeloproliferative Neoplasm
12/25
12/25
NCT05600894: Venetoclax in Combination With ASTX727 for the Treatment of Chronic Myelomonocytic Leukemia and Other Myelodysplastic Syndrome/Myeloproliferative Neoplasm

Recruiting
2
132
Canada, US
Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, Biopsy of Bone Marrow, Biopsy, Bone Marrow, Decitabine and Cedazuridine, ASTX 727, ASTX-727, ASTX727, C-DEC, CDA Inhibitor E7727/Decitabine Combination Agent ASTX727, Cedazuridine/Decitabine Combination Agent ASTX727, Cedazuridine/Decitabine Tablet, DEC-C, Inaqovi, Inqovi, Venetoclax, ABT 199, ABT-0199, ABT-199, ABT199, GDC 0199, GDC-0199, GDC0199, RG7601, Venclexta, Venclyxto
National Cancer Institute (NCI)
Chronic Myelomonocytic Leukemia, Myelodysplastic Syndrome, Myelodysplastic Syndrome With Excess Blasts, Myelodysplastic/Myeloproliferative Neoplasm, Myeloproliferative Neoplasm
08/25
08/25
TAGALONG, NCT05442216: Tagraxofusp and Azaxitadine With or Without Venetoclax in Newly Diagnosed Secondary AML After Hypomethylating Agents

Recruiting
2
53
US
Tagraxofusp (Cycles 1-2), Azacitidine, Tagraxofusp (Cycles 3-12)
Joshua Zeidner, Stemline Therapeutics, Inc., University of North Carolina, Chapel Hill
Acute Myeloid Leukemia
08/27
12/27
Beat AML, NCT03013998: Study of Biomarker-Based Treatment of Acute Myeloid Leukemia

Hourglass Jan 2023 - Mar 2023 : Data from Beat AML trial for acute myeloid leukemia
Recruiting
1/2
2000
US
Samalizumab (BAML-16-001-S1), BI 836858 (BAML-16-001-S2), Laboratory Biomarker Analysis, Daunorubicin (BAML-16-001-S1), Cytarabine (BAML-16-001-S1), Azacitidine (BAML-16-001-S2), AG-221 (BAML-16-001-S3), Enasidenib, Azacitidine (BAML-16-001-S3), Entospletinib (BAML-16-001-S4), GS-9973, ENTO, Azacitidine (BAML-16-001-S4), Entospletinib (BAML-16-001-S5), Decitabine (BAML-16-001-S5), Entospletinib (BAML-16-001-S6), Daunorubicin (BAML-16-001-S6), Cytarabine (BAML-16-001-S6), Pevonedistat (BAML-16-001-S9), TAK-924, MLN4924, Azacitidine (BAML-16-001-S9), AG-120 (BAML-16-001-S16), Azacitidine (BAML-16-001-S16), Gilteritinib (BAML-16-001-S8 Group 1), Decitabine (BAML-16-001-S8 Group 1), AZD5153 (BAML-16-001-S10), Venetoclax (BAML-16-001-S10), TP-0903 (BAML-16-001-S14), Decitabine (BAML-16-001-S14), Decitabine (BAML-16-001-S8 Group 2), Venetoclax (BAML-16-001-S8 Group 2), AZD5991 (BAML-16-001-S18), Azacitidine (BAML-16-001-S18), SNDX-5613 (BAML-16-001-S17), Azacitidine (BAML-16-001-S17), Venetoclax (BAML-16-001-S17), Gilteritinib (BAML-16-001-S8 Group 2), Venetoclax (BAML-16-001-S12 Arm A), Azacitidine (BAML-16-001-S12 Arm A), Venetoclax (BAML-16-001-S12 Arm B), Azacitidine (BAML-16-001-S12 Arm B), ZE46-0134 (BAML-16-001-S21)
Beat AML, LLC
Previously Untreated Relapsed Refractory Acute Myeloid Leukemia
12/26
12/26
BEXMAB, NCT05428969 / 2021-002104-12: A Study to Assess Safety, Tolerability and Preliminary Efficacy of Bexmarilimab in Combination With Standard of Care in Patients With Hematological Malignancies

Recruiting
1/2
181
Europe, US
Bexmarilimab, FP-1305, Azacitidine, Venetoclax, Venclyxto®
Faron Pharmaceuticals Ltd, Faron Pharmaceuticals Ltd
Acute Myeloid Leukemia, Chronic Myelomonocytic Leukemia, Myelodysplastic Syndromes, Relapsed/Refractory AML
04/25
12/25
GFH009X2101, NCT04588922: Study of SLS009 (Formerly GFH009) a Potent Highly Selective CDK9 Inhibitor in Patients With Hematologic Malignancies

Recruiting
1/2
160
US, RoW
SLS009, GFH009, venetoclax, Venclexta, azacitidine, Vidaza, azacytidine
Sellas Life Sciences Group, Sellas Life Sciences Group
Hematologic Malignancies
06/25
12/25
DSP-5336-101, NCT04988555: A Study of DSP-5336 in Relapsed/refractory AML/ ALL with or Without MLL Rearrangement or NPM1 Mutation

Recruiting
1/2
70
Europe, Canada, Japan, US, RoW
DSP-5336
Sumitomo Pharma America, Inc.
Leukemia, Myeloid, Acute, Leukemia, Lymphocytic, Acute
01/25
02/25
ZN-d5-004C, NCT05682170: Study of the ZN-d5 and ZN-c3 in Subjects With Acute Myeloid Leukemia (AML)

Hourglass Jul 2024 - Dec 2024 : Preliminary data r/r/ AML
Terminated
1/2
40
US
ZN-d5 ZN-c3, Study Drug, ZN-c3
K-Group Alpha, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc.
Acute Myeloid Leukemia (AML)
07/24
07/24
SL03-OHD-104, NCT05275439: Phase 1 Study of Shattuck Labs (SL)-172154 in Subjects with MDS or AML

Active, not recruiting
1
160
Europe, Canada, US
SL-172154, Azacitidine, Venetoclax
Shattuck Labs, Inc.
Acute Myeloid Leukemia, Myelodysplastic Syndromes
11/24
11/24
NCT04872478: Pharmacokinetic and Safety Study of MRX-2843 in Adolescents and Adults With Relapsed/Refractory AML, ALL, or MPAL

Recruiting
1
50
US
MRX-2843
Meryx, Inc.
Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Mixed Phenotype Acute Leukemia
07/24
12/24
Pavicic, Eva
NCT04388839: Evolutionary Therapy for Rhabdomyosarcoma

Recruiting
2
28
US
Vincristine, Cyclophosphamide, Vinorelbine, Navelbine, Actinomycin D, Cosmegen, Cyclophosphamide Pill
H. Lee Moffitt Cancer Center and Research Institute, National Pediatric Cancer Foundation
Rhabdomyosarcoma
08/26
08/27
CA209-9WW, NCT03628209: Nivolumab or Nivolumab and Azacitidine in Patients With Recurrent, Resectable Osteosarcoma

Active, not recruiting
1/2
21
US
Nivolumab, Opdivo®, Azacitidine, Vidaza®, Post Treatment Surgery, Standard of Care, Resection of disease
H. Lee Moffitt Cancer Center and Research Institute, Bristol-Myers Squibb
Osteosarcoma, Osteosarcoma in Children, Osteosarcoma Recurrent, Sarcoma
12/24
12/25
Zhang, Jack
TMS-EEG, NCT06241508: The Modulatory Effect of Low-intensity Priming Intermittent Theta Burst Stimulation on Motor Cortex Poststroke: a Concurrent Study

Recruiting
N/A
30
RoW
Transcranial magnetic stimulation
The Hong Kong Polytechnic University
Stroke
02/25
06/25
NCT06503484: Utilizing a Brain-Computer Interface for Observational Imitation Training to Enhance Upper Limb Motor Recovery Post-Stroke: A Randomized Controlled Trial

Not yet recruiting
N/A
44
RoW
Brain-computer interface, Sham brain-computer interface
The Hong Kong Polytechnic University, Tung Wah Hospital
Stroke
06/25
12/25
Cuffee, Juanita
NCT02945800: Nab-Paclitaxel and Gemcitabine for Recurrent/Refractory Sarcoma

Active, not recruiting
2
59
US
nab-Paclitaxel, Abraxane, Gemcitabine, Gemzar
H. Lee Moffitt Cancer Center and Research Institute, National Pediatric Cancer Foundation
Osteosarcoma, Ewing Sarcoma, Rhabdomyosarcoma, Soft Tissue Sarcoma
02/25
02/26
NCT03118986: RCT of Olanzapine for Control of CIV in Children Receiving Highly Emetogenic Chemotherapy

Recruiting
2
200
Canada, US, RoW
Olanzapine, Placebo Oral Tablet
The Hospital for Sick Children, University of California, San Francisco, Children's Mercy Hospital Kansas City, St. Justine's Hospital, Columbia University, Medical University of South Carolina, CancerCare Manitoba, University of North Carolina, Chapel Hill, Nationwide Children's Hospital
Vomiting in Infants and/or Children, Nausea, Hematopoietic System--Cancer, Oncology
03/25
04/25
NCT04388839: Evolutionary Therapy for Rhabdomyosarcoma

Recruiting
2
28
US
Vincristine, Cyclophosphamide, Vinorelbine, Navelbine, Actinomycin D, Cosmegen, Cyclophosphamide Pill
H. Lee Moffitt Cancer Center and Research Institute, National Pediatric Cancer Foundation
Rhabdomyosarcoma
08/26
08/27
NCT04337177: Flavored, Oral Irinotecan VAL-413 (Orotecan®) Given With Temozolomide for Treatment of Recurrent Pediatric Solid Tumors

Recruiting
1
20
US
VAL-413, Orotecan®, Temozolomide, Temodar, Temodal, Temcad, TMZ
Valent Technologies, LLC
Solid Tumors, Neuroblastoma, Rhabdomyosarcoma, Ewing Sarcoma, Hepatoblastoma, Medulloblastoma
06/25
06/25
NCT04372524: Biomarker Verification in Pediatric Chronic GvHD: ABLE 2.0 / PTCTC GVH 1901 Study

Recruiting
N/A
350
Canada, US
University of British Columbia
Chronic Graft-versus-Host-Disease, Leukemia, Allogeneic Hematopoietic Stem Cell Transplantation, Blood Cancer, Non-Malignant Hematologic and Lymphocytic Disorder
01/24
01/25
Markey, Janell
EQUATE, NCT03763318: A Study to Evaluate the Safety, Tolerability, PK, PD, and Clinical Activity of EQ001 in Subjects With aGVHD

Completed
1b/2
30
US
EQ001, Bmab600, Itolizumab, EQ001 Placebo
Equillium, Biocon Limited
Acute-graft-versus-host Disease, aGVHD, GVHD, GVHD, Acute
11/22
11/22
McKinney, Allison
TAGALONG, NCT05442216: Tagraxofusp and Azaxitadine With or Without Venetoclax in Newly Diagnosed Secondary AML After Hypomethylating Agents

Recruiting
2
53
US
Tagraxofusp (Cycles 1-2), Azacitidine, Tagraxofusp (Cycles 3-12)
Joshua Zeidner, Stemline Therapeutics, Inc., University of North Carolina, Chapel Hill
Acute Myeloid Leukemia
08/27
12/27
BEXMAB, NCT05428969 / 2021-002104-12: A Study to Assess Safety, Tolerability and Preliminary Efficacy of Bexmarilimab in Combination With Standard of Care in Patients With Hematological Malignancies

Recruiting
1/2
181
Europe, US
Bexmarilimab, FP-1305, Azacitidine, Venetoclax, Venclyxto®
Faron Pharmaceuticals Ltd, Faron Pharmaceuticals Ltd
Acute Myeloid Leukemia, Chronic Myelomonocytic Leukemia, Myelodysplastic Syndromes, Relapsed/Refractory AML
04/25
12/25
Richardson, Daniel
DISCOVERY, NCT06296368: Evaluating a Decision Support Tool for Adults Seen in Hematology/Oncology Clinics

Recruiting
N/A
500
US
Preference Reporting to Improve Management and Experience (PRIME)
UNC Lineberger Comprehensive Cancer Center, National Cancer Institute (NCI)
Hematologic Malignancies, Lymphoma, Multiple Myeloma, Leukemia, Blood Cancers
09/28
09/28
NCT05061095: Understanding What Matters Most to Patients: Establishing the Validity of a Best-Worst Scaling Survey

Completed
N/A
51
US
Assessment Surveys, Qualitative Interviews
UNC Lineberger Comprehensive Cancer Center, National Institute of Nursing Research (NINR)
Hematologic Neoplasms
09/23
09/23
Jessup, Jewell
NCT05481151: A Study to Assess Efficacy, Safety, and Tolerability of P1101 in Adult Patients With PV

Hourglass Feb 2024 - Dec 2024 : Topline data for adults with PV
Active, not recruiting
3
111
Canada, US
P1101 (Ropeginterferon alfa-2b-njft), Ropeginterferon alfa-2b-njft (P1101)
PharmaEssentia
Polycythemia Vera
12/24
07/25
EXCEED ET, NCT05482971: A Single-arm, Multicenter Study to Assess the Efficacy, Safety, and Tolerability of P1101 in Adults With ET

Active, not recruiting
2
91
Canada, US
Ropeginterferon alfa-2b-njft (P1101), P1101
PharmaEssentia
Essential Thrombocythemia
03/27
03/27

Download Options